Svenska
MENUMENU

“Pancreatic cancer is one of the most aggressive and difficult cancers to diagnose. When detected at an early stage, 5-year survival rates are greatly improved; however, currently, most diagnosed cases are in late stages. It is for this and other reasons that a test for early detection is critical. Immunovia’s IMMray™ PanCan-d has the potential of being such tool, and we are looking forward to be part of this large validation study to reveal its clinical value.”
Dr. Randall Brand, Director, GI Malignancy Early Detection, Diagnosis and Prevention Program at University of Pittsburgh.

MOVIE
Immunovia and
IMMray™ technology
(10 min)


Financial reports

August 2018

Immunovia AB published the company’s Interim Report January-June 2018 on Friday, August 24, 2018, at 08:30 a.m. CET.

Financial reports

Calendar

21-24 September, 2018
AACR, Pancreatic Cancer: Advances in Science and Clinical Care
Place: Boston, MA, USA
27 September, 2018
Labtech Forum
Place: Bonnier Conference Center, Stockholm, Sweden
2-5 October, 2018
World CDx Boston 2018
Place: Boston, Massachusetts, USA
All events
Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports